Last reviewed · How we verify

NCT00995800: FLT2503

A Double-blind, Randomised, Incomplete Block, Crossover, Placebo-controlled, Dose-response Study to Assess Bronchial Hyperresponsiveness and Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adult Subjects With Mild to Moderate Asthma

Completed Phase 2 Last updated 22 October 2018
What this trial tests

Phase 2 trial testing Fluticasone propionate / Formoterol fumarate in Asthma in 46 participants. Completed in 1 July 2010.

Timeline
1 October 2009
Primary endpoint
1 July 2010
1 July 2010

Quick facts

Lead sponsorMundipharma Research Limited
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment46
Start date1 October 2009
Primary completion1 July 2010
Estimated completion1 July 2010
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Mundipharma Research Limited — full company profile →

Who can join

Adults 18 to 55, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

This is a dose-response study to determine how various measurements of airway inflammation respond to high and low dose FlutiForm®, and compared to placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Mundipharma Research Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00995800.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing